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Running head: Smoking and colorectal cancer prognosis in CHANCES 
 
Key Message 
In this individual patient data meta-analysis examining the association between smoking and 
CRC prognosis, former and current smoking were associated with poorer survival. In addition, 
smoking cessation was associated with improved prognosis in comparison with current 
smoking. Future studies should further quantify the benefits of not smoking for CRC prevention 
and prognosis. 
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Abstract 
Background 
Smoking has been associated with colorectal cancer (CRC) incidence and mortality in previous studies 
and might also be associated with prognosis after CRC diagnosis. However, current evidence on 
smoking in association with CRC prognosis is limited.  
Patients and methods 
For this individual patient data meta-analysis, sociodemographic and smoking behavior information of 
12,414 incident CRC patients (median age at diagnosis: 64.3 years), recruited within 14 prospective 
cohort studies among previously cancer-free adults, was collected at baseline and harmonized across 
studies. Vital status and causes of death were collected for a mean follow-up time of 5.1 years following 
cancer diagnosis. Associations of smoking behavior with overall and CRC-specific survival were 
evaluated using Cox regression and standard meta-analysis methodology. 
Results 
A total of 5,229 participants died, 3,194 from CRC. Cox regression revealed significant associations 
between former (hazard ratio (HR)=1.12; 95%-confidence interval (CI)=1.04-1.20) and current smoking 
(HR=1.29; 95%CI=1.04-1.60) and poorer overall survival compared with never smoking. Compared with 
current smoking, smoking cessation was associated with improved overall (HR<10years=0.78; 95%CI=0.69-
0.88; HR≥10years=0.78; 95%CI=0.63-0.97) and CRC-specific survival (HR≥10years=0.76; 95%CI=0.67-0.85). 
Conclusion 
In this large meta-analysis including primary data of incident CRC patients from 14 prospective cohort 
studies on the association between smoking and CRC prognosis, former and current smoking were 
associated with poorer CRC prognosis compared with never smoking. Smoking cessation was 
associated with improved survival when compared with current smokers. Future studies should further 
quantify the benefits of non-smoking, both for cancer prevention and for improving survival among CRC 
patients, in particular also in terms of treatment response. 
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Introduction 
Tobacco smoking is a well-known risk factor for many diseases, including colorectal 
adenomas [1, 2] and colorectal cancer (CRC) [3-8]. In addition, it has been associated with 
increased overall [9, 10] as well as CRC-specific mortality [3, 11, 12] in previously cancer-free 
individuals. With improvements in cancer therapy and a growing number of cancer survivors it 
becomes increasingly important to also evaluate smoking behavior in association with 
prognosis among already diagnosed CRC patients. 
In a meta-analysis on the association between pre-diagnostic smoking and CRC 
prognosis after diagnosis, current smoking was significantly associated with a 26% poorer 
overall survival compared with never smoking [13]. Similarly, Zhu [14] and Yang et al. [15] 
reported significantly increased overall mortality for current compared with never smokers in 
analyses among CRC survivors, and Walter et al. [16] observed a poorer survival in smokers 
with ≥20 pack years compared with never smokers, among CRC patients with nonmetastatic 
disease. 
However, current evidence on smoking and its association with prognosis after CRC 
diagnosis is still very limited due to the few available published studies, which are mainly from 
the US, and the heterogeneity in exposure and outcome assessment as well as in confounder 
adjustment across studies. Time since smoking cessation has rarely ever been investigated in 
association with CRC prognosis [14, 15, 17, 18]. We therefore aimed to provide a 
comprehensive assessment of the impact of smoking status and time since smoking cessation 
on overall and CRC-specific survival using an individual patient data meta-analysis within a 
large consortium of population-based cohorts. 
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Material and Methods 
Study design and study population 
Our investigation included 12,414 CRC patients, recruited within 14 population-based 
cohort studies from 10 different countries participating in the CHANCES consortium 
(Consortium on Health and Ageing: Network of Cohorts in Europe and the U.S.; 
www.chancesfp7.eu). CHANCES aims to identify determinants of health and quality of life in 
older adults. Details pertaining to the recruitment of participants, data collection, and data 
harmonization of cohorts included in CHANCES have been described elsewhere [19-21], and a 
summary of key characteristics of the incident CRC patients from these studies included in this 
analysis is provided in Table 1. 
All studies in the CHANCES consortium have been conducted according to the 
Declaration of Helsinki. For each study, local ethical approval and informed consent from all 
study participants was obtained in accordance with local requirements. 
CRC patients were selected from first incident cases (cancer free before CRC) 
ascertained by active follow-up or record linkage with national/regional cancer registries for all 
cohorts. CRC was defined according to the 10th edition of the International Classification of 
Diseases (ICD-10) codes C18-20. CRC stage was defined based on the Union for International 
Cancer Control classification as: stage I if tumor size (T) equal to 1 or 2, stage II if T equal to 3 
or 4 but no lymph node involved (N=0), stage III if lymph nodes were involved (N≥1) but with no 
evidence of distant metastases (M≠1), and stage IV if distant metastases were present (M=1). 
Pooled mean time between cohorts’ baseline to CRC diagnosis was 6.3 years and pooled 
mean follow-up time after CRC diagnosis was 5.1 years. 
Covariate measurement 
Current smoking status and time since smoking cessation information were acquired, 
either via self-administered questionnaires or via interview. This information was obtained at 
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baseline in each study, i.e. before CRC diagnosis and before the start of follow-up. Current 
smoking status was categorized into never, former and current smoking and includes the 
smoking status at baseline. Current smoking was defined as either regular or daily smoking, 
dependent on the respective study’s definition. Never smoking was defined as either never 
having smoked daily/regularly or as having smoked ≤100 cigarettes over one’s lifetime. Time 
since smoking cessation was calculated in former smokers, taking age at cancer diagnosis 
minus age at smoking cessation (as reported before diagnosis, at recruitment into the 
respective cohorts). Time since smoking cessation was then categorized into two groups: 
smoking cessation <10 years ago and cessation ≥10 years ago. A more detailed categorization 
of smoking cessation was not possible in all cohorts due to the small number of cases. Except 
for the MORGAM-FI and the Rotterdam Study (RS), all included studies reported time since 
smoking cessation for former smokers. 
Each study obtained dates and causes of death from official registers or death 
certificates. Follow-up times started at the time of a patient’s CRC diagnosis and continued until 
the endpoint was reached or until a study’s observation time ended. Outcome measures of 
interest were overall and CRC-specific mortality, with endpoints being death from any cause 
and death from CRC, respectively. 
Further sociodemographic and lifestyle information was collected within the CHANCES 
studies via self-administered questionnaire at baseline. Covariates of interest for our survival 
analysis included age, sex, cancer stage, body mass index (BMI), alcohol consumption, 
education, physical activity and history of diabetes. Cancer stage information was not available 
for the present analyses for the following cohorts: EPIC-Elderly NL, MORGAM (-FI, -NI, -SE), 
RS, TROMSØ, and VIP. Physical activity was not available for the present analyses in 
MORGAM-FI and MORGAM–SE and history of diabetes was not available in MORGAM-FI. All 
other covariate information was available in all of the included studies. 
Statistical analysis 
8 
 
The number of CRC patients with complete data and the distribution of covariates and 
smoking variables within each of the CHANCES studies were evaluated in descriptive 
analyses. Cox proportional hazards regression was conducted to evaluate hazard ratios (HR) 
and 95% confidence intervals (CI) for the association between smoking behavior and survival 
after CRC diagnosis. In addition to crude estimates, we report estimates from models with three 
different, a priori defined levels of adjustment: (A) adjustment for age (continuous) and sex, (B) 
additional adjustment for BMI (continuous; in kg/m²), daily alcohol intake (continuous; in g/day), 
education (primary, secondary, university), vigorous physical activity (yes, no), tumor site 
(colon, rectum) and history of diabetes (yes, no), (C) additional adjustment for cancer stage (I, 
II, III, IV, missing). Only studies with available cancer stage were therefore included in analyses 
using model C adjustment. Survival analyses were first conducted separately for each of the 
included studies, using pre-defined SAS version 9.3 (SAS Institute, Cary, NC) analysis scripts 
supplied to all included studies. Cohort-specific results were then pooled using random effects 
meta-analysis. Random-effects models allow for a variation of true effects across all included 
studies and were computed using Microsoft Excel 2010 (Redmond, WA) according to methods 
described by DerSimonian and Laird [22]. Heterogeneity among the included studies was 
evaluated by the I² index [23, 24].  
The main analyses were conducted on the whole patient sample. Because metastatic 
CRC patients may benefit less from quitting smoking, we performed additional analyses 
restricted to non-metastatic disease (stage I-III) patients only. Because the time interval 
between smoking exposure assessment and CRC diagnosis varied within and between cohorts 
(mean=6 years), we stratified the analyses according to recent and distant time since smoking 
exposure assessment, defined as below and above the mean time since smoking exposure 
assessment, respectively. Additional analyses were conducted stratified by cancer site to 
investigate potentially differing associations between colon and rectal cancer patients.  
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Results 
Descriptive analyses 
Covariate distributions among the 12,414 incident CRC cases from the 14 included 
CHANCES studies are shown in Tables 1 and 2. In total, 63% were men and the median age at 
CRC diagnosis was 64.3 years. Our analytic sample included 34% never, 49% former and 16% 
current smokers. Of 6,110 former smokers, in 5,839 information on time since smoking 
cessation was available, with a median of 23.6 years of cessation at diagnosis and a proportion 
of 24% of patients who stopped smoking <10 years ago and 76% who stopped ≥10 years ago. 
Cancer stage was available in a total of 3,935 study participants with 25% stage I, 31% stage II, 
26% stage III and 18% stage IV CRC. Median BMI in the sample was 26.7 kg/m² and median 
alcohol consumption was 3.1 g/day. The total number of deaths in our total study sample was 
5,229, with 3,194 cases of CRC-specific death. 
Prognosis according to smoking behavior 
Pooled results of survival analyses among all included patients are shown in Table 3, 
and stratified by study in Figure 1. When compared with never smoking, significant associations 
between former (HR=1.12; 95% CI=1.04-1.20) and current smoking (HR=1.29; 95% CI=1.04-
1.60) and poorer overall survival were found. With the exception of crude estimates in former 
smokers, the significant associations were robust to all covariate adjustments. Relevant 
between study heterogeneity could not be seen in analyses on former smoking, but was quite 
high in analyses on current smoking (I²=64%, p<0.05) (Figure 1). In sensitivity analyses where 
NIH-AARP was removed from the pooled estimate, heterogeneity was reduced to I²=5% and 
the association between current smoking and overall survival to borderline significance 
(HR=1.16; 95% CI=0.99-1.35). Looking at time since smoking cessation, in comparison with 
current smokers, having stopped smoking <10 years or ≥10 years ago was significantly 
associated with improved overall survival, even after comprehensive adjustment 
(HR<10years=0.78; 95% CI=0.69-0.88; HR≥10years=0.78; 95% CI=0.63-0.97). In terms of direction 
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and magnitude, found associations between smoking behavior and overall survival show a very 
homogeneous picture across all adjustment settings.  
In analyses of CRC-specific survival, in comparison with never smokers, significant 
associations between current smoking and poorer survival were seen for both crude and age 
and sex adjusted estimates. However, in model B and C only nonsignificant associations were 
observed. In analyses of time since smoking cessation, compared with current smokers, 
significant associations between ≥10 years since smoking cessation and improved CRC-
specific survival were found (HR=0.76; 95% CI=0.67-0.85), and the association was robust 
throughout the different covariate adjustments. No associations were found between <10 years 
since smoking cessation and CRC-specific survival.  
An additional adjustment for stage, where available, did not change hazard ratio 
estimates for smoking status or cessation and overall or CRC-specific survival. Likewise, no 
change in model results was observed when comparing association estimates with and without 
adjustment for stage in only those studies that reported on stage (Data not shown). 
Pooled results from stage-specific analyses among stage I-III patients, conducted only 
on studies with available stage information, are shown in Table 4. Compared with never 
smokers, significant associations were observed between former smoking and poorer overall 
survival (HR=1.17; 95% CI=1.07-1.28) for all levels of adjustment. Associations between 
current smoking and survival were more pronounced than for former smoking, but did not 
remain significant after model A or C adjustment. When looking at time since smoking 
cessation, significant associations were seen between ≥10 years of cessation and improved 
overall survival and in model C also between <10 years of cessation and improved overall 
survival. In the crude Cox model significant associations were observed between current 
smoking and poorer CRC-specific survival, although these associations were not significant 
after multivariate adjustment. No associations were seen between former smoking and CRC-
specific survival. For time since smoking cessation, similar to models on overall survival, we 
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found significant associations between ≥10 years of cessation and improved CRC-specific 
survival in comparison with current smokers, but no association with <10 years of cessation. 
Table 5 shows pooled results of survival analyses of associations between smoking 
variables and survival, conducted in subgroups of patients according to time from smoking 
behavior assessment until CRC diagnosis. Overall, results were comparable between recent 
and distant assessment of smoking behavior groups, although of slightly lower magnitude 
among those with a more distant exposure assessment. In both groups former (HRRecent=1.15; 
95% CI=1.05-1.26; HRDistant=1.13; 95% CI=1.01-1.25) and current smoking (HRRecent=1.41; 95% 
CI=1.12-1.77; HRDistant=1.30; 95% CI=1.08-1.57) were significantly associated with poorer 
overall survival when compared with never smoking. Compared with current smokers, patients 
with <10 years since smoking cessation had improved overall survival irrespective of exposure 
ascertainment timing. In contrast, smoking cessation ≥10 years ago was associated with 
improved overall survival only in the recent exposure assessment group. Looking at CRC-
specific survival, current smokers showed associations with poorer survival in both groups, 
although estimates were more pronounced in the recent assessment group (HRRecent=1.37; 
95% CI=1.18-1.59; HRDistant=1.22; 95% CI=1.03-1.43). In terms of smoking cessation time, <10 
years of cessation was significantly associated with improved survival only in distantly 
assessed patients and ≥10 years was significantly associated with improved survival in recently 
assessed patients. 
Supplementary Table 1 shows associations between the smoking variables and 
survival, conducted in subgroups of patients according to cancer site. Current smoking was 
associated with poorer overall survival in both colon and rectal cancer patients, while for former 
smoking associations seem more pronounced in rectal cancer patients. Looking at CRC-
specific survival, associations were likewise more pronounced in rectal cancer patients. 
Associations between increasing time since smoking cessation and improved survival were 
significant and consistent irrespective of the regarded cancer site subgroup. 
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Discussion 
This individual patient data meta-analysis based on data from 12,414 CRC patients 
collected within the CHANCES consortium showed significant associations between former and 
current smoking and poorer overall survival. Compared with current smoking, smoking 
cessation was associated with improved overall survival independent of time of cessation and 
with improved CRC-specific survival in former smokers with ≥10 years since cessation. Results 
were comparable in nonmetastatic CRC patients. Associations between current smoking and 
poorer overall and CRC-specific survival were most pronounced when smoking exposure had 
been ascertained <6 years before CRC diagnosis. 
Smoking is a well-known risk factor for many adverse health outcomes including CRC 
and its precursors [1, 3, 12]. Previous studies have shown that smoking might also be 
associated with an adverse prognosis in CRC after diagnosis [13]. However, the number of 
studies examining this issue is limited, especially on exposure measures exceeding simple 
assessments of smoking status only. A previous meta-analysis summarized current evidence 
on smoking behavior and its association with CRC prognosis, finding that studies mostly 
assessed overall survival rather than CRC-specific survival [13].  
Studies on former smoking in association with overall survival have reported mixed 
results [18, 25-27] and when pooled, revealed a nonsignificant association [13]. In more recent 
analyses, Yang et al. found a significant association between former smoking and poorer 
overall survival, while Zhu et al. [14] found no association and Walter et al. [16] likewise, even 
when examining only former smokers with ≥20 pack years compared with never smokers. In 
this current analysis, with a much larger sample size than previous studies on former smoking, 
we found a significant association between former smoking and a 10-12% higher overall 
mortality when compared with never smoking. A possible explanation might be indeed the large 
sample size in the current investigation, providing the statistical power needed to reveal such 
rather modest associations. In addition, former smokers certainly represent a very diverse 
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group, with differences in time since cessation, smoking duration and intensity, and in their 
reasons for smoking cessation, as this could be a health or lifestyle choice. Overall though, 
effect magnitudes seem comparable with previous meta-analysis results showing a 
nonsignificant but 11% increased mortality among former compared with never smokers [13]. 
Prediagnostic current smoking has been investigated in association with CRC prognosis 
in previous studies [14-18, 25-32] and has been shown to be significantly associated with 
poorer overall survival when compared with never smokers in a previous meta-analysis [13]. 
Likewise, Yang [15] and Zhu et al. [14] reported significant associations between current 
smoking and poorer overall survival. Walter et al. [16] found a significant association between 
current smoking in combination with ≥20 pack years and poorer overall survival, when 
compared with never smokers. The results of our current investigation are in accordance with 
this, and the magnitude of the observed hazard ratios seems comparable between the previous 
[13] and the current meta-analysis (with a mortality increase of 26% and 29% (Model C) 
respectively). 
Previous investigations on smoking and CRC-specific survival have been sparse. Only 
seven studies investigated smoking status in association with this outcome [15, 16, 18, 26, 30-
32]. Five studies compared current with never [15, 16, 18, 26, 32], three studies former with 
never [15, 18, 26], one study current with former/never [30] and two studies ever with never 
smokers [18, 31]. Results have been mixed but associations were strongest between current or 
ever smoking and poorer CRC-specific survival [15, 18, 30]. In our analysis of 12,414 CRC 
patients, we observed statistically nonsignificant associations between current smoking and 
poorer CRC-specific survival, but former smoking was not associated with CRC-specific 
survival. 
In our study we found higher mortality associated with current smoking to be more 
pronounced in rectal cancer patients. In colon cancer patients associations were only present 
when looking at overall survival. In previous studies CRC site subgroups have rarely been 
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investigated [14, 16, 18, 25, 26]. Previously found associations between smoking and 
decreased survival have been mainly restricted to colon cancer, but were comparable between 
overall and CRC-specific survival [14, 16, 18, 25, 26]. In rectal cancer, previous results have 
been non-significant and inconclusive [14, 16, 18, 26]. These mixed results emphasize on the 
need for larger investigations in these subgroups, to clarify how smoking might worsen 
prognosis depending on cancer site. 
Smoking cessation in association with CRC prognosis has rarely been investigated in 
previous studies [14, 15, 17, 18]. In our analysis, compared with current smokers, we observed 
associations of both short and long durations of cessation with improved overall survival. All 
previous studies on this topic compared persons who had stopped smoking with never smokers 
and only two previous studies found significant associations between time since cessation and 
poorer overall survival compared with never smokers [15, 18]. McCleary and Zhu et al. did not 
observe such associations [14, 17]. Based on current and previous results this topic certainly 
warrants further research.  
Concerning CRC-specific mortality, only two previous studies investigated the 
association between years since smoking cessation and CRC-specific survival, lacking a clear 
trend [15, 18].  In our analysis, we saw highly significant associations between longer time 
since smoking cessation and reduced mortality by ~25%, in comparison with current smokers. 
Considering that at the same time no significant association between current compared with 
never smoking and CRC-specific survival was found, this seems a bit controversial, suggesting 
a larger mortality reduction by smoking cessation for ≥10 years than by never smoking. 
However, found associations, although not significant, go into the same effect direction and the 
lack of significance for the mortality risk estimates of current compared with never smokers is 
supposedly just an issue of insufficient sample size, lacking the power to reach significance.  
In analyses stratified by time of smoking exposure assessment, significant associations 
between smoking and CRC prognosis remained evident. However, associations were more 
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pronounced in patients with a more recent exposure assessment than in patients with an 
assessment ≥6 years ago. Presumably, the information ascertained <6 years before diagnosis 
can be considered more likely to resemble the real exposure present before, at or after CRC 
diagnosis, than the information ascertained ≥6 years ago, which might have led to a reduction 
in misclassification. In addition, some long-term current smokers might have already died 
before a potential CRC diagnosis, leading to an underestimation of effects that is potentially 
larger with increasing time since information ascertainment. 
The biologic mechanisms behind observed adverse associations between smoking and 
prognosis should also be considered. First of all, smokers are at an increased risk for surgical 
complications [33]. Furthermore, in previous studies nicotine was shown to inhibit chemo- and 
radiotherapy response in vitro and in vivo [34, 35]. Vincenzi et al. [36] found associations 
between cigarette smoking and a decreased response to cetuximab-based chemotherapy and 
a shorter time to progression in CRC patients. Nicotine may also activate certain pathways that 
stimulate proliferation and suppress apoptosis in colon cancer cells [37]. In addition, nicotine 
could enhance cell migration and therefore support cancer progression [38]. In previous 
studies, smoking has also been found to be differentially associated with CRC prognosis 
dependent on certain molecular subtypes of tumors, although the reported results were mixed 
[14, 18, 39]. Overall, biologic mechanisms underlying the association of smoking with CRC 
prognosis are not yet fully understood. Smoking prevention and cessation have been shown to 
be beneficial for many health outcomes and similar recommendations are warranted for cancer 
survivors as well, even if the full potential for CRC prognosis improvement requires more 
precise quantification and explanation. 
This study includes one of the largest samples ever assembled to study smoking in 
association with CRC prognosis. We were able to combine studies from multiple countries, 
each of which was analyzed according to a common protocol including comprehensive 
adjustment for potential confounding factors. We included not only overall, but also CRC-
specific survival as outcomes and were also able to investigate the association between 
16 
 
smoking cessation and prognosis, which has rarely ever been investigated in previous studies. 
With our very large study sample we covered a wide geographical area which improves 
generalizability of results.  
Limitations also need to be discussed. First, information on smoking exposure was 
collected not at CRC diagnosis but up to several years before (Mean: 6.3 years), which might 
have led to misclassification, in particular for smokers who might have quit or resumed smoking 
between data collection and CRC diagnosis. This may have led to an underestimation of 
detrimental effects of current smoking and of beneficial effects of smoking cessation, a 
conclusion that is supported by our findings of stronger effects among patients with shorter time 
interval between smoking ascertainment and CRC diagnosis. 
Unfortunately, it was not possible to evaluate smoking intensity, duration, different 
tobacco products, or postdiagnostic smoking behavior in our analysis. For our evaluation, we 
used smoking behavior at baseline, assuming no change in behavior until diagnosis and after, 
which is prone to misclassification bias. In addition, we cannot exclude the presence of residual 
confounding through unmeasured factors, such as e.g. second-hand smoke. Moreover, we 
lacked information on changes in lifestyle over time, which is unfortunate, as time varying 
models might have offered a more accurate insight into the quantification of changes in 
mortality risk associated with changes in lifestyle over time. We did not conduct competing risk 
analyses due to the very low number of non-CRC deaths in some of the cohorts. Although we 
tried to adjust our analyses for stage, this was unfortunately not possible in all of our included 
studies and in all of the patients due to the large number of missing values in cohorts for whom 
cancer stage was collected. Nevertheless, analyses with and without adjustment for stage 
showed no meaningful differences (Data not shown).  
In our analyses of the association between current smoking and overall survival 
(compared with never smokers), heterogeneity was quite high. In particular the NIH-AARP 
cohort includes a supposedly quite selected study population of potentially more health-
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conscious people (70% of persons with college or university education) which might result in an 
underrepresentation of current smokers in our analytic sample and a lower self-report bias and 
might explain some of the found heterogeneity between studies. Furthermore, heterogeneity 
might result from differential age distributions between studies and, in a conservative approach, 
we decided to report only random effects estimates. Although data were harmonized between 
studies according to a common scheme, the studies’ designs and methods used for collection 
of exposure variables and covariates were not completely uniform. Also, we may assume that 
heavy and/or long-term smoking might be underrepresented in our analysis, creating a possible 
survivor bias, with those smokers remaining in our cohorts being on average a slightly hardier 
group. Therefore, our estimates might underestimate the real association between current 
smoking and poorer prognosis. We cannot exclude that social desirability might also have 
played a role in our exposure measurement which usually leads to an underreporting of 
smoking.  
In conclusion, in this large meta-analysis examining the association between smoking 
and CRC prognosis, former as well as current smoking were associated with poorer overall 
survival. We showed smoking cessation to be associated with improved overall and CRC-
specific survival in comparison with current smoking. Future studies should further quantify the 
benefits of not smoking, both for cancer prevention and for improving survival among CRC 
patients, in particular also in terms of interactions between smoking and treatment response. 
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Figure legends: 
 
Figure 1: Forest plots for the association between former and current smoking (Reference: Never smoking) and 
overall and CRC-specific survival. Abbreviations: HR=Hazard ratio; CI=Confidence interval; CRC=Colorectal 
cancer. Abbreviated study names: COSM=Cohort of Swedish Men; DK=Denmark; EPIC=European Prospective 
Investigation into Cancer and Nutrition; ES=Spain; ESTHER=Early Recognition and Optimized Treatment of 
Chronic Diseases in the Older Population; GR=Greece; MORGAM=Multinational Monitoring of Trends and 
Determinants in Cardiovascular Diseases (MONICA) Risk, Genetics, Archiving and Monograph; MORGAM 
FI=Finrisk Study (Finland); MORGAM NI=PRIME Belfast Study (Northern Ireland); MORGAM SE=Northern 
Sweden MONICA examinations (Norrbotten county only); NIH-AARP=National Institute of Health – American 
Association of Retired Persons; NL=The Netherlands; RS=Rotterdam Study; SMC=Swedish Mammography 
Cohort; TROMSØ=The Tromsø Study; VIP=Västerbotten Intervention Programme  
¹HRs and 95% CIs were adjusted for: Sex, age, BMI, education, alcohol intake, tumor site, diabetes and vigorous 
physical activity; estimates from COSM, EPIC -DK/-ES/-GR, ESTHER, NIH-AARP and SMC were additionally 
adjusted for tumor stage; adjustment for vigorous physical activity was not possible for MORGAM FI and SE; 
adjustment for diabetes was not possible in MORGAM FI
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Table 1: Socio-demographic and lifestyle characteristics at baseline of the incident colorectal cancer cases included for cohorts in the CHANCES consortium 
 COSM EPIC ESTHER MORGAM NIH-AARP RS SMC TROMSØ VIP DK ES GR NL FI NI SE 
Variable N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) 
Total 901 330 93 88 153 160 342 76 54 8214 257 612 340 794 
Median follow-up after diagnosis (y) 2 2 3 2 3 4 5 3 3 5 3 3 3 3 
Age at diagnosis (y)1 66 
(59-72) 
63 
(61-64) 
62 
(61-64) 
68 
(65-71) 
65 
(62-67) 
65 
(61-69) 
55 
(47-61) 
56 
(53-58) 
66 
(55-69) 
65 
(61-68) 
68 
(63-74) 
66 
(58-72) 
66 
(58-72) 
59 
(50-60) 
Sex               
Male 901 (100) 179 (54) 56 (60) 50 (57) 10 (7) 100 (63) 179 (52) 76 (100) 22 (41) 5523 (67) 115 (45) - 185 (54) 407 (51) 
Female - 151 (46) 37 (40) 38 (43) 143 (93) 60 (38) 163 (48) - 32 (59) 2691 (33) 142 (55) 612 (100) 155 (46) 387 (49) 
Cancer stage               
I 68 (15) 0 (0) 0 (0) 0 (0) n.a. 0 (0) n.a. n.a. n.a. 868 (31) n.a. 47 (15) n.a. n.a. 
II 159 (34) 83 (73) 34 (74) 20 (100) n.a. 77 (50) n.a. n.a. n.a. 765 (27) n.a. 89 (28) n.a. n.a. 
III 125 (27) 12 (11) 7 (15) 0 (0) n.a. 51 (33) n.a. n.a. n.a. 719 (25) n.a. 104 (33) n.a. n.a. 
IV 109 (24) 18 (16) 5 (11) 0 (0) n.a. 27 (17) n.a. n.a. n.a. 472 (17) n.a. 76 (24) n.a. n.a. 
Tumor location               
Colon 558 (62) 191 (58) 58 (62) 57 (65) 115 (75) 95 (60) 199 (58) 38 (51) 33 (61) 6013 (73) 128 (50) 434 (71) 241 (71) 512 (64) 
Rectum 343 (38) 139 (42) 35 (38) 31 (35) 38 (25) 63 (40) 143 (42) 37 (49) 21 (39) 2201 (27) 129 (50) 178 (29) 99 (29) 282 (36) 
BMI (kg/m²)1,2 26 
(24-28) 
26 
(24-29) 
29 
(27-32) 
29 
(26-32) 
26 
(23-29) 
28 
(26-31) 
27 
(25-31) 
27 
(25-28) 
27 
(25-30) 
27 
(24-30) 
26 
(24-28) 
25 
(23-27) 
26 
(24-29) 
26 
(24-28) 
Alcohol (g/day)1,2 9 
(3-19) 
13 
(5-35) 
9 
(0-31) 
1 
(0-12) 
2 
(0-7) 
5 
(0-13) 
2 
(0-9) 
14 
(0-38) 
1 
(0-4) 
2 
(0-15) 
3 
(0-15) 
3 
(0-7) 
2 
(0-5) 
2 
(0-6) 
Education2               
Primary 661 (74) 126 (38) 80 (87) 73 (84) 50 (33) 120 (75) 210 (62) 0 (0) 25 (46) 73 (1) 62 (24) 481 (79) 203 (60) 305 (40) 
Secondary 113 (13) 142 (43) 10 (11) 8 (9) 86 (57) 31 (20) 110 (33) 68 (89) 19 (35) 2338 (29) 171 (67) 28 (5) 84 (25) 341 (44) 
College or university 122 (14) 60 (18) 2 (2) 6 (7) 16 (11) 8 (5) 18 (5) 8 (11) 10 (19) 5547 (70) 22 (9) 103 (17) 52 (15) 124 (16) 
Vigorous Physical activity2             
No 552 (63) 53 (26) 90 (98) 67 (77) 68 (46) 109 (68) n.a. 68 (89) n.a. 4606 (57) 24 (16) 418 (71) 230 (69) 555 (78) 
Yes 318 (37) 152 (74) 2 (2) 20 (23) 81 (54) 51 (32) n.a. 8 (11) n.a. 3529 (43) 122 (84) 170 (29) 102 (31) 158 (22) 
History of diabetes2             
No 818 (91) 300 (96) 82 (88) 76 (86) 144 (94) 128 (80) n.a. 75 (99) 51 (94) 7239 (88) 245 (96) 583 (95) 325 (96) 768 (97) 
Yes 83 (9) 11 (4) 11 (12) 12 (14) 9 (6) 32 (20) n.a. 1 (1) 3 (6) 975 (12) 11 (4) 29 (5) 13 (4) 26 (3) 
Smoking status2              
Never 298 (33) 83 (25) 52 (56) 49 (56) 83 (54) 66 (42) 151 (44) 18 (24) 26 (48) 2545 (31) 97 (38) 343 (56) 107 (31) 352 (44) 
Former 372 (41) 116 (35) 19 (20) 29 (33) 50 (33) 70 (44) 125 (37) 35 (47) 17 (31) 4642 (57) 111 (43) 136 (22) 143 (42) 245 (31) 
Current 231 (26) 131 (40) 22 (24) 10 (11) 20 (13) 22 (14) 66 (19) 22 (29) 11 (20) 1027 (13) 49 (19) 133 (22) 90 (26) 197 (25) 
Time since smoking cessation (y)3             
Median 26 23 22 20 26 21 n.a. 13 20 n.a. n.a. 24 18 25 
<10 years 21 (6) 12 (11) 2 (11) 2 (7) 3 (6) 16 (23) n.a. 13 (37) 1 (6) 1244 (27) n.a. 11 (8) 44 (31) 15 (7) 
≥10 years 346 (94) 94 (89) 17 (89) 26 (93) 46 (94) 54 (77) n.a. 22 (63) 16 (94) 3398 (73) n.a. 125 (92) 99 (69) 212 (93) 
Abbreviations (in alphabetical order): COSM=Cohort of Swedish Men; Diag=Diagnosis; DK=Denmark; EPIC=European Prospective Investigation into Cancer and Nutrition; ES=Spain; ESTHER=Early Recognition and 
Optimized Treatment of Chronic Diseases in the Older Population; GR=Greece; MORGAM=Multinational Monitoring of Trends and Determinants in Cardiovascular Diseases (MONICA) Risk, Genetics, Archiving and 
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Monograph; MORGAM FI=Finrisk Study (Finland); MORGAM NI=PRIME Belfast Study (Northern Ireland); MORGAM SE=Northern Sweden MONICA examinations (Norrbotten county only); n.a.=Not available; NIH-
AARP=National Institute of Health – American Association of Retired Persons; NL=The Netherlands; RS=Rotterdam Study; SMC=Swedish Mammography Cohort; TROMSØ=The Tromsø Study; VIP=Västerbotten 
Intervention Programme; y=Years. Percentages calculated after exclusion of missing values; some percentage totals exceed 100% due to rounding. 
1Continuous variable described by median and interquartile range 
2Information collected at time of recruitment into the study (baseline), preceding cancer diagnosis 
3Former smokers only 
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Table 2: Pooled characteristics of all included CRC patients in total and according to vital status 
Variable Total Alive 
Dead 
Death from any 
cause Death from CRC 
N (%) N (%) N (%) N (%) 
Total 12414 (100) 7185 (58) 5229 (42) 3194 (26) 
Age (y)1 64.3 (59.3-67.7) 62.9 (58.6-66.8) 65.5 (60.5-68.8) 64.7 (59.4-68.2) 
Sex         
  Male 7803 (63) 4443 (62) 3360 (64) 1971 (62) 
  Female 4611 (37) 2742 (38) 1869 (36) 1223 (38) 
Cancer Stage2         
  I 983 (25) 803 (34) 180 (12) 49 (5) 
  II 1227 (31) 881 (37) 346 (22) 156 (16) 
  III 1018 (26) 606 (25) 412 (27) 275 (28) 
  IV 707 (18) 105 (4) 602 (39) 514 (52) 
Tumor location         
  Colon 8672 (70) 5007 (70) 3656 (70) 2202 (69) 
  Rectum 3739 (30) 2177 (30) 1571 (30) 991 (31) 
BMI (kg/m²)1 26.7 (24.2-29.6) 26.6 (24.2-29.4) 26.8 (24.2-29.8) 26.6 (24.0-29.5) 
Alcohol (g/day)1 3.1 (0.5-14.5) 3.1 (0.6-14.3) 3.0 (0.3-14.6) 3.4 (0.5-15.1) 
Education   
  Primary 2469 (20) 1177 (17) 1292 (25) 850 (27) 
  Secondary 3549 (29) 2058 (29) 1491 (29) 899 (29) 
  University 6098 (50) 3790 (54) 2308 (45) 1365 (44) 
Vigorous Physical activity 
  No 6840 (59) 3926 (58) 2914 (61) 1751 (61) 
  Yes 4713 (41) 2874 (42) 1839 (39) 1132 (39) 
History of diabetes 
  No 11153 (90) 6614 (92) 4539 (87) 2865 (90) 
  Yes 1239 (10) 563 (8) 676 (13) 319 (10) 
Smoking status         
  Never 4270 (34) 2595 (36) 1675 (32) 1121 (35) 
  Former 6110 (49) 3579 (50) 2531 (48) 1453 (45) 
  Current 2031 (16) 1010 (14) 1021 (20) 619 (19) 
Time since smoking cessation (y)3 
Median (IQR) 23.6 (15.3-32.3) 25.4 (16.5-34.4) 22.5 (13.5-30.7) 22.6 (13.9-30.9) 
  <10 years 1384 (24) 774 (22) 610 (26) 331 (25) 
  ≥10 years 4455 (76) 2678 (78) 1777 (74) 1017 (75) 
Abbreviations: CRC=Colorectal cancer; y=Years, IQR=Interquartile range 
1Continuous variable described by median and IQR. Summary median and IQR were calculated from cohort-specific medians and IQRs and pooled 
by weighting on the sample size within each given subgroup (i.e. overall, among those alive, among those dying from any-cause, and among those 
dying from CRC). Some percentage totals exceed 100% due to rounding. 
2Information on cancer stage was available and thus these analyses were restricted to data from the following cohorts: COSM, EPIC DK, EPIC ES, 
EPIC GR, ESTHER, NIH-AARP and SMC. 
3Former smokers only; data on smoking cessation were not available for MORGAM FI and RS. 
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Table 3: Summary hazard ratios and 95% confidence intervals derived from meta-analyses with CHANCES cohort-specific estimates for the association of smoking status 
and time since smoking cessation with overall and CRC-specific survival in all CRC patients 
 At risk Events 
HR (95% CI) 
Crude Model A1 Model B2 Model C3 
Overall survival       
Smoking status 
  Never 4278 1679 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
  Former 6112 2531 1.07 (0.97-1.18) 1.10 (1.03-1.18) 1.12 (1.04-1.20) 1.12 (1.04-1.20) 
  Current 2032 1022 1.23 (1.04-1.46) 1.25 (1.05-1.49) 1.28 (1.04-1.57) 1.29 (1.04-1.60) 
Time since smoking cessation4 
  Current smokers 1916 947 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
  <10 years 1333 589 0.85 (0.68-1.07) 0.81 (0.67-0.99) 0.78 (0.69-0.88) 0.78 (0.69-0.88) 
  ≥10 years 4506 1770 0.80 (0.69-0.93) 0.77 (0.65-0.92) 0.76 (0.60-0.96) 0.78 (0.63-0.97) 
CRC-specific survival       
Smoking status 
  Never 4278 1124 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
  Former 6112 1453 1.00 (0.92-1.08) 0.98 (0.91-1.07) 1.00 (0.91-1.09) 1.00 (0.91-1.09) 
  Current 2032 620 1.20 (1.06-1.35) 1.15 (0.98-1.35) 1.14 (0.94-1.38) 1.15 (0.95-1.41) 
Time since smoking cessation4 
  Current smokers 1916 570 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
  <10 years 1333 305 0.97 (0.63-1.48) 0.94 (0.62-1.44) 0.82 (0.55-1.24) 0.84 (0.60-1.20) 
  ≥10 years 4506 1049 0.77 (0.69-0.86) 0.76 (0.68-0.84) 0.75 (0.66-0.86) 0.76 (0.67-0.85) 
Abbreviations: CRC=Colorectal cancer; HR=Hazard ratio; CI=Confidence interval 
¹Model A was adjusted for sex and age 
2Model B was adjusted for: Sex, age, BMI, education, alcohol intake, tumor site (colon/rectum), diabetes and vigorous physical activity; adjustment for vigorous physical activity was not possible in MORGAM FI and SE; 
adjustment for diabetes was not possible in MORGAM FI 
3Model C was adjusted for all covariates adjusted for in Model B, and where possible, additionally for stage 
4Since time since smoking cessation information was not available for the MORGAM FI and Rotterdam Study (RS), the number of current smokers in the reference category also excludes patients from these two 
studies; in analyses on smoking status these two studies were not excluded 
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Table 4: Summary hazard ratios and 95% confidence intervals derived from meta-analyses with CHANCES cohort-
specific estimates for the association of smoking status and time since smoking cessation with overall and CRC-
specific survival in stage I-III CRC patients¹ 
 At risk Events 
HR (95% CI) 
Crude Model A2 Model C3 
Overall survival      
Smoking status      
  Never 2857 863 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
  Former 4812 1716 1.19 (1.09-1.31) 1.16 (1.06-1.26) 1.17 (1.07-1.28) 
  Current 1280 569 1.36 (1.05-1.76) 1.26 (0.89-1.77) 1.32 (0.92-1.89) 
Time since smoking cessation      
  Current 1280 290 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
  <10 years 1192 484 1.06 (0.61-1.84) 0.90 (0.59-1.37) 0.75 (0.65-0.86) 
  ≥10 years 3608 1226 0.69 (0.59-0.80) 0.71 (0.56-0.90) 0.76 (0.54-1.07) 
CRC-specific survival      
Smoking status      
  Never 2857 532 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
  Former 4812 893 1.04 (0.94-1.16) 1.03 (0.92-1.15) 1.00 (0.79-1.27) 
  Current 1280 290 1.26 (1.03-1.55) 1.02 (0.69-1.52) 1.11 (0.72-1.70) 
Time since smoking cessation      
  Current 1280 290 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
  <10 years 1192 232 1.50 (0.67-3.34) 1.35 (0.64-2.83) 1.15 (0.53-2.50) 
  ≥10 years 3608 659 0.76 (0.64-0.91) 0.76 (0.62-0.94) 0.72 (0.61-0.84) 
¹Analyses were restricted to data from the following cohorts with available tumor stage information: COSM, EPIC DK, EPIC ES, EPIC GR, 
ESTHER, NIH-AARP and SMC.  
²Model A was adjusted for sex and age 
3Model C was adjusted for sex, age, BMI, education, alcohol intake, tumor site, diabetes, vigorous physical activity and tumor stage 
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Table 5: Summary hazard ratios and 95% confidence intervals derived from meta-analyses with CHANCES cohort-specific estimates for the association of smoking status 
and time since smoking cessation with overall and CRC-specific survival in all CRC patients according to time between smoking exposure assessment and CRC diagnosis 
 
Recent assessment of smoking exposure¹ Distant assessment of smoking exposure¹ 
At risk Events HR (95% CI)² At risk Events HR (95% CI)² 
Overall survival       
Smoking status       
  Never 2068 895 1.00 (Reference) 2202 780 1.00 (Reference) 
  Former 3342 1529 1.15 (1.05-1.26) 2768 1002 1.13 (1.01-1.25) 
  Current 900 547 1.41 (1.12-1.77) 1131 474 1.30 (1.08-1.57) 
Time since smoking cessation³       
  Current 881 533 1.00 (Reference) 1035 414 1.00 (Reference) 
  <10 years 812 404 0.79 (0.65-0.97) 521 185 0.80 (0.65-0.99) 
  ≥10 years 2461 1080 0.69 (0.54-0.90) 2045 690 0.88 (0.67-1.15) 
CRC-specific survival       
Smoking status       
  Never 2068 571 1.00 (Reference) 2202 550 1.00 (Reference) 
  Former 3342 838 1.01 (0.90-1.14) 2768 615 1.04 (0.91-1.18) 
  Current 900 320 1.37 (1.18-1.59) 1131 299 1.22 (1.03-1.43) 
Time since smoking cessation³       
  Current 881 311 1.00 (Reference) 1035 259 1.00 (Reference) 
  <10 years 812 202 0.70 (0.41-1.21) 521 103 0.76 (0.57-1.00) 
  ≥10 years 2461 617 0.74 (0.64-0.86) 2045 432 0.89 (0.69-1.15) 
Abbreviations: CRC=Colorectal cancer; HR=Hazard ratio; CI=Confidence interval 
¹Smoking exposure assessment was considered recent or distant if ascertained <6 years or ≥6 years before CRC diagnosis, respectively 
²HRs and 95% CIs were adjusted for: Sex, age, BMI, education, alcohol intake, tumor site, diabetes and vigorous physical activity; adjustment for vigorous physical activity was not possible in MORGAM FI and SE; 
adjustment for diabetes was not possible in MORGAM FI 
³Since time since smoking cessation information was not available for MORGAM FI and Rotterdam Study (RS), the number of current smokers in the reference category also excludes patients from these two studies; in 
analyses on smoking status these two studies were not excluded 
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Supplementary Table 1: Summary hazard ratios and 95% confidence intervals derived from meta-analyses with CHANCES cohort-specific estimates for the association of 
smoking status and time since smoking cessation with overall and CRC-specific survival in all CRC patients according to cancer site 
 
Colon cancer patients Rectal cancer patients 
At risk Events HR (95% CI)1 At risk Events HR (95% CI)1 
Overall survival       
Smoking status       
  Never 3044 1204 1.00 (Reference) 1226 471 1.00 (Reference) 
  Former 4256 1746 1.07 (0.95-1.20) 1854 785 1.20 (1.03-1.39) 
  Current 1372 706 1.33 (1.02-1.74) 659 315 1.39 (1.07-1.81) 
Time since smoking cessation2       
  Current 1308 665 1.00 (Reference) 608 282 1.00 (Reference) 
  <10 years 977 431 0.76 (0.65-0.87) 356 158 0.90 (0.71-1.15) 
  ≥10 years 3137 1231 0.71 (0.54-0.93) 1369 539 0.75 (0.60-0.94) 
CRC-specific survival       
Smoking status       
  Never 3044 815 1.00 (Reference) 1226 306 1.00 (Reference) 
  Former 4256 978 0.93 (0.83-1.04) 1854 475 1.24 (1.03-1.49) 
  Current 1372 409 1.13 (0.87-1.47) 659 210 1.51 (1.19-1.90) 
Time since smoking cessation2       
  Current 1308 386 1.00 (Reference) 608 184 1.00 (Reference) 
  <10 years 977 212 0.74 (0.60-0.92) 356 93 0.99 (0.72-1.35) 
  ≥10 years 3137 718 0.76 (0.60-0.96) 1369 331 0.79 (0.63-1.00) 
Abbreviations: CRC=Colorectal cancer; HR=Hazard ratio; CI=Confidence interval 
1HRs and 95% CIs were adjusted for: Sex, age, BMI, education, alcohol intake, tumor site, diabetes and vigorous physical activity; adjustment for vigorous physical activity was not possible in MORGAM FI and SE; 
adjustment for diabetes was not possible in MORGAM FI 
2Since time since smoking cessation information was not available for MORGAM FI and Rotterdam Study (RS), the number of current smokers in the reference category also excludes patients from these two studies; in 
analyses on smoking status these two studies were not excluded 
 
 
